Authors:
BOS GMJ
VANPUTTEN WLJ
VANDERHOLT B
VANDENBENT M
VERDONCK LF
HAGENBEEK A
Citation: Gmj. Bos et al., FOR WHICH PATIENTS WITH AGGRESSIVE NON-HODGKINS-LYMPHOMA IS PROPHYLAXIS FOR CENTRAL-NERVOUS-SYSTEM DISEASE MANDATORY, Annals of oncology, 9(2), 1998, pp. 191-194
Authors:
LOKHORST HM
SONNEVELD P
CORNELISSEN JJ
CROOCKEWIT S
VANDERHOLT B
KOOY MV
VANOERS RHJ
RICHEL D
SEGEREN C
VELLENGA E
VERDONCK LF
VERHOEF G
WIJERMANS PW
Citation: Hm. Lokhorst et al., VAD AND INTERMEDIATE-DOSE MELPHALAN (IDM) INDUCTION THERAPY FOLLOWED BY STEM-CELL TRANSPLANTATION IN MULTIPLE-MYELOMA - RESULTS OF A PHASE-II AND PRELIMINARY-RESULTS OF A RANDOMIZED PHASE-III STUDY, Bone marrow transplantation, 21, 1998, pp. 709-709
Authors:
LOKHORST HM
SONNEVELD P
CORNELISSEN JJ
CROOCKEWIT S
VANDERHOLT B
KOOY MV
VANOERS RHJ
RICHEL D
SEGEREN C
VELLENGA E
VERDONCK LF
VERHOEF G
WIJERMANS PW
Citation: Hm. Lokhorst et al., VAD AND INTERMEDIATE-DOSE MELPHALAN (IDM) FOLLOWED BY STEM-CELL TRANSPLANTATION IN MULTIPLE-MYELOMA - RESULTS OF A PHASE-II AND PRELIMINARY-RESULTS OF A RANDOMIZED PHASE-III STUDY, British Journal of Haematology, 102(1), 1998, pp. 6-7
Authors:
BROERS A
HENZENLOGMANS S
KUENENBOUMEESTER V
DELARIVIERE GB
VANDERHOLT B
LOWENBERG B
CORNELISSEN JJ
Citation: A. Broers et al., TRANSPLANT-RELATED MORTALITY FOLLOWING ALLOGENEIC BMT IN CMV SEROPOSITIVE DONOR RECIPIENT PAIRS IS INCREASED DESPITE EFFICACIOUS PREVENTIONOF CMV DISEASE BY PREEMPTIVE THERAPY WITH GANCICLOVIR/, British Journal of Haematology, 102(1), 1998, pp. 13-13
Authors:
DOORDUIJN JK
VANDERHOLT B
BREED WPM
VANDERHEM KG
VANIMHOFF GW
KRAMER MHH
KOOY MV
VANOERS MHJ
OSSENKOPPELE GJ
RICHEL DJ
ROOZENDAAL KJ
VANTVEER MB
VERDONCK LF
VERHOEF G
WIJERMANS PW
SONNEVELD P
Citation: Jk. Doorduijn et al., EFFICACY OF STANDARD CHOP CHEMOTHERAPY IN ELDERLY PATIENTS WITH POOR-RISK NON-HODGKINS-LYMPHOMA (NHL), British Journal of Haematology, 102(1), 1998, pp. 149-149
Authors:
GRATAMA JW
KRAAN J
ADRIAANSEN H
HOOIBRINK B
LEVERING W
REINDERS P
VANDENBEEMD MWM
VANDERHOLT B
BOLHUIS RLH
Citation: Jw. Gratama et al., REDUCTION OF INTERLABORATORY VARIABILITY IN FLOW CYTOMETRIC IMMUNOPHENOTYPING BY STANDARDIZATION OF INSTRUMENT SET-UP AND CALIBRATION, AND STANDARD LIST MODE DATA-ANALYSIS, Cytometry, 30(1), 1997, pp. 10-22
Authors:
GRATAMA JW
VANDERLINDEN R
VANDERHOLT B
BOLHUIS RLH
VANDEWINKEL JGJ
Citation: Jw. Gratama et al., ANALYSIS OF FACTORS CONTRIBUTING TO THE FORMATION OF MONONUCLEAR CELLAGGREGATES (ESCAPEES) IN FLOW CYTOMETRIC IMMUNOPHENOTYPING, Cytometry, 29(3), 1997, pp. 250-260
Authors:
VANDENHEUVELEIBRINK MM
VANDERHOLT B
TEBOEKHORST PAW
PIETERS R
SCHOESTER M
LOWENBERG B
SONNEVELD P
Citation: Mm. Vandenheuveleibrink et al., MDR-1 EXPRESSION IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RESPONSE ANDSURVIVAL IN DE-NOVO ACUTE MYELOID-LEUKEMIA, British Journal of Haematology, 99(1), 1997, pp. 76-83
Authors:
SEGEREN CM
VANDERHOLT B
SONNEVELD P
CROOCKEWIT S
VELLENGA E
VANOERS MHJ
RICHEL D
VERHOEF G
CORNELISSEN JJ
LOKHORST HM
Citation: Cm. Segeren et al., VAD ADMINISTERED AS INTRAVENOUS PUSH INJECTION AS FIRST-LINE TREATMENT IN STAGE II III MULTIPLE-MYELOMA/, Blood, 90(10), 1997, pp. 1591-1591
Authors:
CONTANT CME
VANGEEL AN
VANDERHOLT B
WIGGERS T
Citation: Cme. Contant et al., THE PEDICLED OMENTOPLASTY AND SPLIT SKIN-GRAFT (POSSG) FOR RECONSTRUCTION OF LARGE CHEST-WALL DEFECTS - A VALIDITY STUDY OF 34 PATIENTS, European journal of surgical oncology, 22(5), 1996, pp. 532-537
Authors:
WITJES MJH
SPEELMAN OC
NIKKELS PGJ
NOOREN CAAM
NAUTA JM
VANDERHOLT B
VANLEENGOED HLLM
STAR WM
ROODENBURG JLN
Citation: Mjh. Witjes et al., IN-VIVO FLUORESCENCE KINETICS AND LOCALIZATION OF ALUMINUM PHTHALOCYANINE DISULFONATE IN AN AUTOLOGOUS TUMOR-MODEL, British Journal of Cancer, 73(5), 1996, pp. 573-580
Authors:
VANDENHEUVELEIBRINK MM
VANDERHOLT B
TEBOEKHORST PAW
PIETERS R
LOWENBERG B
SCHOESTER M
SONNEVELD P
Citation: Mm. Vandenheuveleibrink et al., MDR-1 EXPRESSION IS A SIGNIFICANT ADVERSE PROGNOSTIC FACTOR IN DE-NOVO AML FOR CR AND SURVIVAL AND IS INDEPENDENT FROM AGE, KARYOTYPE AND PHENOTYPE, Blood, 88(10), 1996, pp. 1428-1428
Authors:
OLIE RA
LOOIJENGA LHJ
DEKKER MC
DEJONG FH
VANDISSELEMILIANI F
DEROOIJ DG
VANDERHOLT B
OOSTERHUIS JW
Citation: Ra. Olie et al., HETEROGENEITY IN THE IN-VITRO SURVIVAL AND PROLIFERATION OF HUMAN SEMINOMA CELLS, British Journal of Cancer, 71(1), 1995, pp. 13-17
Authors:
OSSENKOPPELE GJ
VERHOEF GEG
VANDERHOLT B
VERDONCK LF
VELLENGA E
SONNEVELD P
VANDERLELIE J
WIJERMANS PW
LOWENBERG B
Citation: Gj. Ossenkoppele et al., RANDOMIZED PHASE-II STUDY ON THE VALUE OF G-CSF (FILGRASTIM) IN COMBINATION WITH STANDARD INDUCTION CHEMOTHERAPY IN MYELODYSPLASTIC SYNDROMES (MDS), Blood, 86(10), 1995, pp. 1338-1338